Welcome! This blog contains research & information on lifestyle, nutrition and health for those with MS, as well as continuing information on the understanding of the endothelium and heart-brain connection. This blog is informative only--all medical decisions should be discussed with your own physicians.

The posts are searchable---simply type in your topic of interest in the search box at the top left.

Almost all of MS research is initiated and funded by pharmaceutical companies. This maintains the EAE mouse model and the auto-immune paradigm of MS, and continues the 20 billion dollar a year MS treatment industry. But as we learn more about slowed blood flow, gray matter atrophy, and environmental links to MS progression and disability--all things the current drugs do not address--we're discovering more about how to help those with MS.

To learn how this journey began, read my first post from August, 2009. Be well! Joan

Showing posts with label Fasudil. Show all posts
Showing posts with label Fasudil. Show all posts

Sunday, July 31, 2011


 Fasudil, cerebral blood flow and Michael J. Fox

July 31, 2011 at 1:36pm

In the news today, Michael J. Fox's foundation for Parkinson's research has awarded a grant to study a relatively new drug that improves cerebral blood flow after ischemic injury.  What is interesting is that this drug is also being studied as a treatment for MS.  This is the kind of drug that makes sense; one that helps after axonal death due to ischemia.   Let's also hope that CCSVI and the International Society for Neurovascular Disease research provides more answers for those with Parkinson's.
____________________________________________________________________

GRAND RAPIDS -- Actor Michael J. Fox's foundation for Parkinson's research has awarded a $400,000 grant to fund research by Grand Rapids scientists into a drug that has the potential to halt the progression of the disease.

The focus of their efforts is Fasudil, a drug already approved in Japan to improve blood flow to the brain in stroke victims. It has shown similar positive outcomes in the U.S. in late-stage clinical trials.

Fasudil also showed potential for improving learning and memory and reducing the risk of Alzheimer's in a 2009 study by TGen and Arizona State University. VARI investigators discovered its potential for treating Parkinson's while testing drugs to reduce the toxicity caused by a gene implicated in Parkinson's disease.

"Fasudil has a very favorable safety profile in humans and is already available in Japan as an oral tablet, so upon successful milestone completion, we could be seeing clinical trials within two to three years," MacKeigan said in a statement.
http://news.msu.edu/story/9622/

______________________________________

The reason it is also news for those of us in CCSVI, is because of Fasudil's affect on the endothelium, cerebral blood flow and nitric oxide.  This compound could be very helpful in recovery from brain and spinal cord injury due to CCSVI.   Here are some more studies on this drug:
Read more »
Posted by at No comments:
Labels: , , ,
Subscribe to: Posts (Atom)